Sino Biopharmaceutical Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Sino Biopharmaceutical has a total shareholder equity of CN¥42.1B and total debt of CN¥9.5B, which brings its debt-to-equity ratio to 22.6%. Its total assets and total liabilities are CN¥66.7B and CN¥24.6B respectively. Sino Biopharmaceutical's EBIT is CN¥5.9B making its interest coverage ratio -22.2. It has cash and short-term investments of CN¥13.2B.
Anahtar bilgiler
22.6%
Borç/özkaynak oranı
CN¥9.51b
Borç
Faiz karşılama oranı | -22.2x |
Nakit | CN¥13.18b |
Eşitlik | CN¥42.12b |
Toplam yükümlülükler | CN¥24.58b |
Toplam varlıklar | CN¥66.70b |
Son finansal sağlık güncellemeleri
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
Sep 02Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Recent updates
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar
Oct 02Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
Sep 02Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?
Jul 12Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 1177's short term assets (CN¥25.2B) exceed its short term liabilities (CN¥21.9B).
Uzun Vadeli Yükümlülükler: 1177's short term assets (CN¥25.2B) exceed its long term liabilities (CN¥2.6B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 1177 has more cash than its total debt.
Borcun Azaltılması: 1177's debt to equity ratio has increased from 8.2% to 22.6% over the past 5 years.
Borç Kapsamı: 1177's debt is well covered by operating cash flow (68.1%).
Faiz Kapsamı: 1177 earns more interest than it pays, so coverage of interest payments is not a concern.